Home
report store
phage therapies competitive landscape

phage-therapies-market-forecast-and-competitive-landscape

Phage Therapies - Competitive landscape, 2026

Published Date : 2026

Pages : 2-3 Business days

Region : Global,

Summary
TOC Table of Content
LOT
Companies
- Sample Request

Phage Therapies Competitive landscape

DelveInsight’s, “Phage Therapies Competitive landscape, 2026” report provides comprehensive insights about 20+ companies and 25+ drugs in Phage Therapies Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Phage Therapies Understanding

Phage Therapies Overview

Phage therapy is a medical form of biological control of bacterial infections, one that uses naturally occurring viruses, called bacteriophages or phages, as antibacterial agents. Phage therapy development and interest began over a century ago. Phages are viruses and have all the common viral properties such as they do not replicate outside of their host, they have relatively small genomes, they make extensive use of host machinery for their replication, and they exhibit tight host cell specificity.

Phages are viruses and have all the common viral properties such as they do not replicate outside of their host, they have relatively small genomes, they make extensive use of host machinery for their replication, and they exhibit tight host cell specificity. There are many different types of virion morphologies, but the most common is the double-stranded DNA (dsDNA) tailed phages, in which the DNA is encapsulated within a capsid (head) that is attached to a tail. Infection is initiated by attachment of the tail tip to the bacterial cell wall and injection of the genome from the capsid, through the cell membrane, and into the cytoplasm.

There are three potential impediments to using naturally occurring phages therapeutically:

(1) the only available phages with desired tropisms are temperate,

(2) phages that infect the target bacterial host do not kill it efficiently, and

(3) any of the many phages that code for dozens of proteins of UKF could be potentially harmful. It thus may be necessary to engineer phages with enhanced therapeutic properties, safety features, and host range. For example, phages can be engineered to carry payloads that modulate host responses or reduce the potential for horizontal gene transfer of antibiotic resistance genes by rapidly degrading the bacterial genome.

Such engineering approaches may also allow for the functional and programmed arrangement of phage particles that increased penetrance of biofilms, target intracellular pathogens, or have enhanced PK and PD properties. Construction of such recombinants with increased genome length may encounter packaging constraints of the phage capsids, warranting identification and removal of non-essential genes to increase cloning capacity, similar to strategies used in development of the first phage cloning vectors.

Apart from advantages of phage therapy there are also some constraints of phage therapy in humans. Bacteriophages selectively bind to specific receptors of bacteria, which confer a relatively narrow range of infectivity. This would narrow the infectivity range challenging the choice of phage for therapeutic use. As a minimum requirement, phages used in phage therapy should follow only the lytic pathway to ensure the safety of the patient. Bacterial infections, where the currently isolated phages lack a lytic cycle, are therefore not treatable with phages. Large phage titers trigger the release of neutralizing antibodies in high amounts, which would hinder the action of phages. Geier et al. First observed rapid clearance of phages when Lambda phages were injected in high titers into transgenic mice lacking immune response.

Discover the latest Phage Therapies pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Phage Therapies Pipeline Report Highlights

In January 2026, Locus Biosciences announced a contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), of $3.3 million with further funding of up to a total of $28 million available over the course of the contract if all project milestones are met. The awarded contract will support a proof-of-concept clinical trial of LBP-PA01, an AI-designed bacteriophage therapeutic for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by antibiotic-resistant Pseudomonas aeruginosa bacteria.
In October 2025, Phagos has raised a €25 million ($30 million) Series A round to further develop its bacteriophage drugs used to treat bacterial disease in animals and, eventually, humans. The company calls these drugs “a sustainable answer to the global challenge of bacterial resistance.” It will use the funding to deploy treatments, starting with animal health, as well as further develop its technology that simplifies the discovery process. CapAgro, Hoxton Ventures, CapHorn, and Demeter co-led the round, which also saw participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.
In October 2025, Armata Pharmaceuticals, Inc. highlighted positive results from its recently completed Phase IIa diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus (""S. aureus"") bacteremia (""SAB"") in a late-breaking oral presentation at IDWeek 2025™.
In July 2025, BiomX Inc. announced the publication of a peer-reviewed article in Nature Communications titled, “Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial”. The article notably features previously unreported antimicrobial efficacy data from the Phase Ib/IIa clinical trial and reinforces the strength of BiomX's innovative approach to developing bacteriophage therapies for chronic disease with substantial unmet needs.
In May 2025, Armata Pharmaceuticals, Inc. announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous administered multi-phage therapeutic for the treatment of Staphylococcus aureus bacteremia in the intent-to-treat population.
In January 2024, Locus Biosciences, Inc. announced the release of USD 23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs).
In August 2024, Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase II trial of CRISPR-edited phage therapy candidate LBP-EC01. LBP-EC01 is being developed as a novel treatment for uncomplicated urinary tract infections caused by antimicrobial-resistant and multi-drug-resistant E. coli. The data from the randomized, uncontrolled, open-label trial were published in The Lancet Infectious Diseases.

Phage Therapies: Company and Product Profiles (Marketed Therapies)

1. Company Overview: XX

Product Description: XX

Phage Therapies: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Locus Biosciences

Locus Biosciences is creating a new class of precision bio therapeutics with clinical-stage, engineered bacteriophage treatments for a diverse set of bacterial and microbiome/inflammatory diseases. A world-leading bacteriophage discovery, synthetic biology, and manufacturing platform powers the company. Locus engineer’s bacteriophage – naturally occurring viruses that target bacteria – to: 1) kill pathogenic bacteria, while sparing good bacteria, through programmable, precision anti-bacterials with CRISPR-Cas3; and 2) utilize bacteria resident in the body to deliver therapeutic molecules to reduce inflammation or induce other bio therapeutic effects. Its artificial intelligence and machine-learning based discovery engine is targeting bacteria across therapeutic areas including infectious disease, immunology, and oncology. Multiple non-dilutive strategic partnerships validate the company’s platform and programs. These include anti-bacterial alliances with Biomedical Advanced Research and Development Authority (BARDA) for its lead Phase II asset; and Combatting Antibiotic Resistant Bacteria Accelerator (CARB-X).

Product Description: LBP-EC01

LBP-EC01 is a Locus crPhage therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage and the DNA-targeting activity of CRISPR-Cas3. Laboratory tests and small animal models of urinary tract infection have demonstrated LBP-EC01 is significantly more effective at killing E. coli than corresponding natural bacteriophages, and LBP-EC01 met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase Ib trial. Locus is currently enrolling patients in the ELIMINATE trial, a landmark registration-enabling Phase II/III trial testing LBP-EC01 in acute uncomplicated UTIs caused by MDR E. coli.

2. Company Overview: Technophage

Technophage is a Portugal-based biotechnology company focused on developing bacteriophage-based therapies to address bacterial infections, particularly those driven by antimicrobial resistance (AMR). The company leverages its proprietary phage engineering platform to design highly specific viruses that target and eliminate pathogenic bacteria while preserving beneficial microbiota. Technophage’s pipeline includes investigational products across infectious disease indications, with applications spanning human health, veterinary medicine, and food safety. The company is positioned within the emerging phage therapy space as an alternative approach to conventional antibiotics in drug-resistant infections.

Product Description: TP-102

TP-102 is an investigational bacteriophage-based therapy being developed by Technophage for the treatment of bacterial infections, particularly those associated with antimicrobial resistance. The therapy leverages engineered bacteriophages to selectively target and eliminate pathogenic bacteria while preserving the normal microbiota, offering a precision-based alternative to conventional antibiotics. Preclinical research has demonstrated promising antibacterial activity and specificity, supporting its potential use against difficult-to-treat and multidrug-resistant infections. Technophage is advancing TP-102 as part of its broader phage therapy platform focused on innovative anti-infective solutions. The program is currently in the early development stage, with ongoing studies evaluating its safety, efficacy, and translational potential across targeted infectious disease indications. Currently the drug is in Phase II for the treatment for chronic ulcers.

3. Company Overview: Intralytix, Inc.'s

Intralytix, Inc. is a U.S.-based biotechnology company specializing in the development of bacteriophage-based products for food safety, environmental decontamination, and human health applications. The company is a pioneer in commercial phage technology and focuses on using naturally occurring bacteriophages to selectively target and eliminate foodborne and pathogenic bacteria such as Listeria, Salmonella, and E. coli. Intralytix has developed a broad portfolio of FDA- and USDA-regulated phage products used in food processing and sanitation to reduce microbial contamination and improve public health safety. The company is also advancing phage therapy programs for human infectious diseases, positioning itself as a key player in the emerging antimicrobial resistance (AMR) solutions space.

Product Description: ShigActive™

Intralytix, Inc.'s ShigActive™ bacteriophage therapy targeting Shigella has entered a Phase I/IIa clinical trial at the Center for Vaccine Development at the University of Maryland, Baltimore School of Medicine in Baltimore, MD. ShigActive™ is an investigational oral vaccine candidate being developed to prevent Shigella infections, a major cause of acute diarrheal disease, particularly in children in low- and middle-income countries. It is designed to stimulate both systemic and mucosal immunity to protect against multiple Shigella serotypes responsible for severe gastrointestinal illness. The vaccine leverages an attenuated or engineered antigen-based approach (depending on formulation stage) to generate a targeted immune response while maintaining a strong safety profile. Preclinical and early clinical studies have shown encouraging immunogenicity and the ability to induce protective antibody responses.

ShigActive™ remains in clinical development, with ongoing evaluation focused on safety, dose optimization, and breadth of protection across circulating Shigella strains.

Further product details are provided in the report……..

Phage Therapies Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Phage Therapies Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.